Evolution from double to triple-antimalarial drug combinations (Q38303998)

1 September 2017

1 reference

title

Evolution from double to triple-antimalarial drug combinations (English)

1 reference

1 September 2017

0 references

1

G Dennis Shanks

1 reference

1 September 2017

2

Michael D Edstein

1 reference

1 September 2017

David Jacobus

3

1 reference

1 September 2017

publication date

30 December 2014

1 reference

Transactions of the Royal Society of Tropical Medicine and Hygiene

1 September 2017

number of pages

7

1 reference

based on heuristic

inferred from page(s)

published in

1 reference

1 September 2017

volume

109

1 reference

1 September 2017

issue

3

1 reference

1 September 2017

page(s)

182-188

1 reference

Designing the next generation of medicines for malaria control and eradication

1 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1093/TRSTMH/TRU199

Selection of known Plasmodium falciparum resistance-mediating polymorphisms by artemether-lumefantrine and amodiaquine-sulfadoxine-pyrimethamine but not dihydroartemisinin-piperaquine in Burkina Faso

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/TRSTMH/TRU199

Malaria burden and artemisinin resistance in the mobile and migrant population on the Thai-Myanmar border, 1999-2011: an observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/TRSTMH/TRU199

Optimising strategies for Plasmodium falciparum malaria elimination in Cambodia: primaquine, mass drug administration and artemisinin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/TRSTMH/TRU199

Primaquine therapy for malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/TRSTMH/TRU199

Diagnosis and treatment of Plasmodium vivax malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/TRSTMH/TRU199

CYP450 phenotyping and metabolite identification of quinine by accurate mass UPLC-MS analysis: a possible metabolic link to blackwater fever.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/TRSTMH/TRU199

Primaquine failure and cytochrome P-450 2D6 in Plasmodium vivax malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/TRSTMH/TRU199

Review: Improving the therapeutic index of 8-aminoquinolines by the use of drug combinations: review of the literature and proposal for future investigations

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/TRSTMH/TRU199

Sequential treatment with quinine and mefloquine or quinine and pyrimethamine-sulfadoxine for falciparum malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/TRSTMH/TRU199

Double-blind trial to find dose range using a fixed combination of mefloquine, sulfadoxine and pyrimethamine in falciparum malaria: a field study on adults in Burma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/TRSTMH/TRU199

Emergence of artemisinin-resistant malaria on the western border of Thailand: a longitudinal study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/TRSTMH/TRU199

Amodiaquine alone, amodiaquine sulfadoxine-pyrimethamine, amodiaquine artesunate, and artemether-lumefantrine for outpatient treatment of malaria in Tanzanian children: a four-arm randomised effectiveness trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/TRSTMH/TRU199

Amodiaquine, sulfadoxine/pyrimethamine, and combination therapy for treatment of uncomplicated falciparum malaria in Kampala, Uganda: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/TRSTMH/TRU199

Sulfadoxine/pyrimethamine alone or with amodiaquine or artesunate for treatment of uncomplicated malaria: a longitudinal randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/TRSTMH/TRU199

Randomized trial of artesunate amodiaquine, sulfadoxine-pyrimethamine amodiaquine, chlorproguanal-dapsone and SP for malaria in pregnancy in Tanzania

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/TRSTMH/TRU199

Amodiaquine combined with sulfadoxine/pyrimethamine versus artemisinin-based combinations for the treatment of uncomplicated falciparum malaria in Africa: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/TRSTMH/TRU199

The global pipeline of new medicines for the control and elimination of malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/TRSTMH/TRU199

Incidence of malaria and efficacy of combination antimalarial therapies over 4 years in an urban cohort of Ugandan children

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/TRSTMH/TRU199

Rapid and effective malaria control in Cambodia through mass administration of artemisinin-piperaquine

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/TRSTMH/TRU199

Chlorproguanil-dapsone-artesunate versus artemether-lumefantrine: a randomized, double-blind phase III trial in African children and adolescents with uncomplicated Plasmodium falciparum malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/TRSTMH/TRU199

Chlorproguanil-dapsone-artesunate versus chlorproguanil-dapsone: a randomized, double-blind, phase III trial in African children, adolescents, and adults with uncomplicated Plasmodium falciparum malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/TRSTMH/TRU199

Clinical spectrum and severity of hemolytic anemia in glucose 6-phosphate dehydrogenase-deficient children receiving dapsone

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/TRSTMH/TRU199

The rise and fall of the antimalarial Lapdap: a lesson in pharmacogenetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/TRSTMH/TRU199

Phenotypic changes in artemisinin-resistant Plasmodium falciparum lines in vitro: evidence for decreased sensitivity to dormancy and growth inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/TRSTMH/TRU199

Artemisinin‐induced dormancy in plasmodium falciparum: duration, recovery rates, and implications in treatment failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/TRSTMH/TRU199

Lead optimization of aryl and aralkyl amine-based triazolopyrimidine inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase with antimalarial activity in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/TRSTMH/TRU199

Identification of a metabolically stable triazolopyrimidine-based dihydroorotate dehydrogenase inhibitor with antimalarial activity in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/TRSTMH/TRU199

Antiprotozoal activity of ferroquine

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/TRSTMH/TRU199

Phase I randomized dose-ascending placebo-controlled trials of ferroquine--a candidate anti-malarial drug--in adults with asymptomatic Plasmodium falciparum infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/TRSTMH/TRU199

Pharmacokinetics of ferroquine, a novel 4-aminoquinoline, in asymptomatic carriers of Plasmodium falciparum infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/TRSTMH/TRU199

Antiparasitic agents: new drugs on the horizon

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/TRSTMH/TRU199

Spiroindolones, a potent compound class for the treatment of malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/TRSTMH/TRU199

The spiroindolone drug candidate NITD609 potently inhibits gametocytogenesis and blocks Plasmodium falciparum transmission to anopheles mosquito vector

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/TRSTMH/TRU199

Spiroindolone KAE609 for falciparum and vivax malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/TRSTMH/TRU199

Synthetic ozonide drug candidate OZ439 offers new hope for a single-dose cure of uncomplicated malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/TRSTMH/TRU199

KAF156 is an antimalarial clinical candidate with potential for use in prophylaxis, treatment, and prevention of disease transmission

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/TRSTMH/TRU199

A new primaquine analogue, tafenoquine (WR 238605), for prophylaxis against Plasmodium falciparum malaria

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/TRSTMH/TRU199

Randomized trial of 3-dose regimens of tafenoquine (WR238605) versus low-dose primaquine for preventing Plasmodium vivax malaria relapse

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/TRSTMH/TRU199

Development, evaluation, and application of an in silico model for antimalarial drug treatment and failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093/TRSTMH/TRU199

21 January 2018

Identifiers

DOI

10.1093/TRSTMH/TRU199

1 reference

1 September 2017

1 reference